Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits
Authors:
- 1 November 2008
- journal article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 29 (11) , 1383-1390
Abstract
To study the pharmacokinetics and toxicity of intravitreal erythropoietin (EPO) for potential clinical use. For toxicity study, 4 groups (60 rabbits) with intravitreal injection (IVit) of EPO were studied (10U, 100U, or 1 000U) per eye for single injection and 0.6 U/eye (the designed therapeutic level in rabbits) for monthly injections (6×). Eye examination, flash electroretinogram (ERG), and fluorescein angiography (FA) were carried out before and after injection. The rabbits were killed for histological study at different intervals. For the pharmacokinetic study, after IVit of 5 U EPO into left eyes, 44 rabbits were killed at different intervals, and the EPO levels in vitreous, aqueous, retina and serum were analyzed by enzyme-linked immunosorbent assay. At all of the time points examined, the eyes were within normal limits. No significant ERG or FA change was observed. The histology of retina remained unchanged. The pharmacokinetic profile of EPO in ocular compartments was summarized as follows. The half-life times of EPO in vitreous, aqueous and serum were 2.84, 3.24 and 2.12 d, respectively; and Cmax were 4615.75, 294.31 and 1.60 U/L, respectively. EPO concentrations in the retina of the injected eye peaked at 1.36 U/g protein at 6 h following injection, with the half-life observed to be 3.42 d. IVit of EPO in a wide range is well tolerated and safe for rabbit eyes. At doses up to 10-fold higher than therapeutic levels, EPO has a pharmacokinetic profile with faster clearance, which is favorable for episodic IVit.Keywords
This publication has 18 references indexed in Scilit:
- Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early DiabetesInvestigative Ophthalmology & Visual Science, 2008
- Erythropoietin pharmacologyClinical and Translational Oncology, 2007
- Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transectionExperimental Neurology, 2007
- Expression Pattern of Erythropoietin and Erythropoietin Receptor in Experimental Model of Retinal DetachmentCurrent Eye Research, 2007
- Novel applications of recombinant erythropoietinCurrent Opinion in Pharmacology, 2006
- Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietinEuropean Journal of Pharmaceutical Sciences, 2005
- Intravitreal Administration of Erythropoietin and Preservation of Retinal Ganglion Cells in an Experimental Rat Model of GlaucomaCurrent Eye Research, 2005
- Erythropoietin as an antiapoptotic, tissue-protective cytokineCell Death & Differentiation, 2004
- Diabetic RetinopathySurvey of Ophthalmology, 2002
- High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndromeBritish Journal of Haematology, 1993